Antidepressant pharmacotherapy in the treatment of depression in the very old: A randomized, placebo-controlled trial
Cornell University, Итак, New York, United States American Journal of Psychiatry
(Impact Factor: 12.3).
11/2004; 161(11):2050-9. DOI: 10.1176/appi.ajp.161.11.2050
This study determined the efficacy of antidepressant medication for the treatment of depression in the "old-old."
This randomized 8-week medication trial compared citalopram, 10-40 mg/day, to placebo in the treatment of patients 75 and older with unipolar depression.
A total of 174 patients who were 58% women with a mean age of 79.6 years (SD=4.4) and a mean baseline Hamilton Depression Rating Scale score of 24.3 (SD=4.1) were randomly assigned to treatment at 15 sites. There was a main effect for site but not for treatment condition. The remission rate, defined as a final Hamilton depression scale score <10, was 35% for the citalopram and 33% for the placebo groups. However, patients with severe depression (baseline Hamilton depression scale score >24) tended to have a higher remission rate with medication than with placebo (35% versus 19%).
In the oldest group of community-dwelling patients to be studied to date, medication was not more effective than placebo for the treatment of depression. However, given the considerable psychosocial support received by all patients, the placebo condition represents more than the ingestion of an inactive pill. Across sites, there was considerable range in response to medication, 18% to 82%, and to placebo, 16% to 80%.
Available from: Hyung-Jun Yoon
- "Previous trials comparing the treatment response of atypical antipsychotics based on age (<70 years old, ≥70 years old) suggested that older age might predict a poor response to the treatment of delirium [26,40]. Recently, researchers in the field of psychiatry often divide older subjects into two groups (young-old and old-old), with an age of 74 being the cutoff point [41-43]. However, no previous research has compared the response rate to various atypical antipsychotics in the treatment of delirium based on this age grouping. "
[Show abstract] [Hide abstract]
ABSTRACT: Most previous studies on the efficacy of antipsychotic medication for the treatment of delirium have reported that there is no significant difference between typical and atypical antipsychotic medications. It is known, however, that older age might be a predictor of poor response to antipsychotics in the treatment of delirium. The objective of this study was to compare the efficacy and safety of haloperidol versus three atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) for the treatment of delirium with consideration of patient age.
This study was a 6-day, prospective, comparative clinical observational study of haloperidol versus atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in patients with delirium at a tertiary level hospital. The subjects were referred to the consultation-liaison psychiatric service for management of delirium and were screened before enrollment in this study. A total of 80 subjects were assigned to receive either haloperidol (N = 23), risperidone (N = 21), olanzapine (N = 18), or quetiapine (N = 18). The efficacy was evaluated using the Korean version of the Delirium Rating Scale-Revised-98 (DRS-K) and the Korean version of the Mini Mental Status Examination (K-MMSE). The safety was evaluated by the Udvalg Kliniske Undersogelser side effect rating scale.
There were no significant differences in mean DRS-K severity or K-MMSE scores among the four groups at baseline. In all groups, the DRS-K severity score decreased and the K-MMSE score increased significantly over the study period. However, there were no significant differences in the improvement of DRS-K or K-MMSE scores among the four groups. Similarly, cognitive and non-cognitive subscale DRS-K scores decreased regardless of the treatment group. The treatment response rate was lower in patients over 75 years old than in patients under 75 years old. Particularly, the response rate to olanzapine was poorer in the older age group. Fifteen subjects experienced a few adverse events, but there were no significant differences in adverse event profiles among the four groups.
Haloperidol, risperidone, olanzapine, and quetiapine were equally efficacious and safe in the treatment of delirium. However, age is a factor that needs to be considered when making a choice of antipsychotic medication for the treatment of delirium.Trial registration: Clinical Research Information Service, Republic of Korea, (http://cris.nih.go.kr, Registered Trial No. KCT0000632).
BMC Psychiatry 09/2013; 13(1):240. DOI:10.1186/1471-244X-13-240 · 2.21 Impact Factor
Available from: Patricia R Houck
- "As in our original analysis (Meyers et al., 2009), remission was defined as a Ham-D score of <10 at two consecutive assessments. This definition was chosen because the study was designed to recruit equal numbers of younger and older subjects; a HAM-D score of ≤10 has been a standard cut-off point for defining remission in geriatric antidepressant trials (Arean et al., 2010; Kupfer, 2005; Reynolds et al., 1996; Roose et al., 2004) and has been used in ECT studies that have included patients with MDpsy as well as both younger and older patients (Kellner et al., 2006; Petrides et al., 2001; Sackeim et al., 2001). Remission also required the absence of delusions, (SADS delusional item scores of 1) at the second assessment of the two-assessment remission of depression interval. "
[Show abstract] [Hide abstract]
ABSTRACT: Having failed to respond to an adequate antidepressant treatment course predicts poorer treatment outcomes in patients with major depression. However, little is known about the impact of prior treatment on the outcome of major depression with psychotic features (MDpsy). We examined the effect of prior treatment history on the outcome of pharmacotherapy of MDpsy in patients who participated in the STOPD-PD study, a randomized, double-blind, clinical trial comparing a combination of olanzapine plus sertraline vs. olanzapine plus placebo. The strength of treatment courses received prior to randomization was classified using a validated method. A hierarchy of outcomes was hypothesized based on treatments received prior to randomization and randomized treatment. A high remission rate was observed in subjects with a history of no prior treatment or inadequate treatment who were treated with a combination of olanzapine and sertraline. A low remission rate was observed in subjects who had previously failed to respond to an antidepressant alone and who were treated with olanzapine monotherapy. A low remission rate was also observed in subjects who had previously failed to respond to a combination of an antipsychotic and an antidepressant. Similar to patients with major depression, these results emphasize the impact of prior pharmacotherapy on treatment outcomes in patients with MDpsy.
Journal of Psychiatric Research 02/2011; 45(7):896-901. DOI:10.1016/j.jpsychires.2011.01.003 · 3.96 Impact Factor
Available from: Constantine G Lyketsos
- "Nevertheless, until 2003, only one large placebo-controlled trial of a non-tricyclic antidepressant, marketed in the US, in outpatients 60 years of age or older with major depressive disorder had been published . The first trials of second-generation antidepressants, including a large study of patients aged 75 years and above treated with citalopram, reported no advantage over placebo [4-6] or small drug-placebo differences [3,7], hence the clinical value of these agents in treating older depressed adults was uncertain. "
[Show abstract] [Hide abstract]
ABSTRACT: Escitalopram has shown efficacy and tolerability in the prevention of relapse in elderly patients with major depressive disorder (MDD). This post-hoc analysis compared time to relapse for young-old patients (n = 197) to that for old-old patients (n = 108).
Relapse prevention: after 12-weeks open-label treatment, remitters (MADRS ≤12) were randomised to double-blind treatment with escitalopram or placebo and followed over 24-weeks. Patients were outpatients with MDD from 46 European centers aged ≥75 years (old-old) or 65-74 years of age (young-old), treated with escitalopram 10-20 mg/day. Efficacy was assessed using the Montgomery Åsberg Depression Rating Scale (MADRS).
After open-label escitalopram treatment, a similar proportion of young-old patients (78%) and old-old patients (72%) achieved remission. In the analysis of time to relapse based on the Cox model (proportional hazards regression), with treatment and age group as covariates, the hazard ratio was 4.4 for placebo versus escitalopram (χ(2)-test, df = 1, χ(2)= 22.5, p < 0.001), whereas the effect of age was not significant, with a hazard ratio of 1.2 for old-old versus young-old (χ(2)-test, df = 1, χ(2) = 0.41, p = 0.520). Escitalopram was well tolerated in both age groups with adverse events reported by 53.1% of young-old patients and 58.3% of old-old patients. There was no significant difference in withdrawal rates due to AEs between age groups (χ(2)-test, χ(2) = 1.669, df = 1, p = 0.196).
Young-old and old-old patients with MDD had comparable rates of remission after open-label escitalopram, and both age groups had much lower rates of relapse on escitalopram than on placebo.
BMC Geriatrics 01/2011; 11:2. DOI:10.1186/1471-2318-11-2 · 1.68 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.